pertussis treatment
Oct 11, 2022
Merck’s Sotatercept Trial Result; PARP Rivals Closing in on AstraZeneca and Merck’s Lynparza; FDA Clears GSK’s Boostrix for Pertussis; Fast Track Designation to Nanoscope Therapeutics’s MCO-010; FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab; Solid Biosciences to Acquire AavantiBio
Merck’s Sotatercept Clears Phase III Trial Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin re...
Read More...
Dec 20, 2021
Pertussis Vaccines: Whole-cell & Acellular Vaccines, Different Types & Manufacturers along with the Regimen in Various Age Groups
Pertussis, also commonly known as whooping cough, is a very highly contagious respiratory disease. It is caused by the bacterium Bordetella Pertussis. Pertussis can be a serious disease for people of all ages but especially for babies. Pertussis vaccines offer the best protection against this very contagious diseas...
Read More...
Dec 17, 2021
What is Driving the Pertussis Treatment Market Forward?
Pertussis, which was first discovered in the Paris epidemic of 1578, is distinguished by a 2-week paroxysmal cough, an inspiratory whoop, posttussive emesis, and posttussive syncope. Pertussis is caused by Bordetella pertussis. In 1906, Bordetella pertussis was discovered, and in the 1940s, a vaccine was created. P...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
